Florence holds a PhD in Molecular and Cellular Biology from the Université Louis Pasteur in Strasbourg (France). She gained considerable experience in cell and gene therapies development and regulatory affairs, bringing many of the early cell and gene therapies from the bench to the clinic and to marketing authorisation. She worked, among other companies, at uniQure on the approval of Glybera (first gene therapy) in 2012 and supported the development of a number of AAV-based gene therapy vectors for various disease areas. At Novartis she worked on the worldwide submission and approval of Kymriah (first CAR-T product), on the approvals of Luxturna and Zolgensma, and advised on the development of the cell and gene therapies pipeline. After participating in the building of several biotech start-ups in the Cell Therapy field, she now works as an independent consultant.